The purpose of this review is to systematically examine the available evidence to assess the effectiveness of anthelminthic being channelled into these programmes in a number of developing countries. The limited resource base in developing countries means improve health. With the increased emphasis on helminth control as a cost-effective public health intervention, funds and resources are

The World Development Report (1993) highlighted population interventions for intestinal helminth control as a cost-effective way to this strategy have not been examined.

A second chemotherapeutic strategy utilised in the control of helminth infections is one in which entire populations or segments of populations are treated with intermittent drug therapy (Guyatt 1993). The goal of these programmes is to treat all children to reduce the worm and egg burdens. The secondary aim is to improve their nutritional status and cognition and learning (Nokes 1992, Stephenson 1993). Although studies have shown the effectiveness of available chemotherapeutic agents to decrease parasite rates, not

The difficulty in the design of programmes that use these agents relates to the rapid re-infection rates of treated individuals. The drugs eliminate the adult parasites, but without changes in sanitation and food handling, transmission of new infections is difficult to curtail. The problems of control are related to the difficulty in establishing long term programmes that integrate the use of chemotherapeutic agents and environmental and sanitation programmes. Results of such combined programmes implemented in Japan after the Second World War indicate that comprehensive programmes can be effective in controlling infection rates and transmission of infections. However, these programmes are time and resource intensive (Yokogawa 1985).

Current international anthelminth programmes focus on a chemotherapeutic approach. The programme designers use elaborate mathematical models based on prevalence and treatment studies in developing countries (Anderson 1991). These models indicate that infections are aggregated. That is, a small proportion of the population harbour a large proportion of the worm burden. Children commonly carry the heaviest worm burdens. These models also indicate re-infection patterns and have provided information for decision makers on the frequency of repeat treatment programmes.

Given these infection patterns and the availability of broad spectrum, effective and safe drugs, children are the target of chemotherapeutic control programmes advocated by the WHO (1990 and 1996). The aim of these programmes is to treat all children to reduce the worm and egg burdens. The secondary aim is to improve their nutritional status and cognition and learning (Nokes 1992, Stephenson 1993). Although studies have shown the effectiveness of available chemotherapeutic agents to decrease parasite rates, not all researchers agree that these treatment programmes have an impact on measures of nutritional status and cognition (Greenberg 1981, Lai 1995). Therefore, this treatment strategy needs to be examined by systematic review of the literature that uses nutritional status and cognition measures as outcomes of the assessment of effectiveness.

A second chemotherapeutic strategy utilised in the control of helmint infections is one in which entire populations or segments of populations are treated with intermittent drug therapy (Guyatt 1993). The goal of these programmes has been to decrease the prevalence and intensity of helminths in the overall population and interrupt the transmission cycle (Bundy 1990). Again mathematical models related to aggregation of infections have helped to direct these programmes. However, the effectiveness and long term impact of this strategy have not been examined.

The purpose of this review is to systematically examine the available evidence to assess the effectiveness of anthelminthic
Routine intermittent anthelminth therapy in disadvantaged populations

chemotherapeutic programmes aimed at improving nutrition and learning in children; and those aimed at decreasing prevalence and intensity of infection within populations or communities.

OBJECTIVES

1. To determine the effectiveness of chemotherapeutic helminth therapy in children on their nutritional status and cognition.

2. To determine the effectiveness of chemotherapeutic helminth therapy, either given to the whole population or a targeted subgroup, on prevalence and intensity of intestinal helminths in that population.

Hypotheses tested:

1. Anthelminth chemotherapy treatments in children have no effect on nutritional status or cognition.

2. Anthelminth chemotherapy treatment of populations is not effective in decreasing helminth prevalence and intensity in that population.

CRITERIA FOR CONSIDERING STUDIES FOR THIS REVIEW

Types of studies
All randomised controlled trials in which individuals or groups were treated with drug interventions for intestinal helminths. Trials which used pseudo-randomisation techniques or alternate allocation to treatment or control groups are also being considered.

Types of participants
Children who participated in chemotherapeutic control programmes.

Adults and children residing in areas where mass community chemotherapeutic treatment programmes were conducted.

Types of interventions
Chemotherapy treatment programmes for children within schools or communities.

Community-based chemotherapy programmes where mass treatment of the population or a subgroup of the population was carried out.

The review was limited to treatment with the most common drugs (mebendazole, piperazine, albendazole, levamisole, pyrantel, piperazine, praziquantel, niclosamide, bephenium, tetrachloroethylene, thiabendazole, and ivermectin).

Types of outcome measures

Objective 1
Trials that reported on the treatment of children were included if they reported clinical outcomes such as, nutritional status, growth and development or measurements of cognition or learning. Data related to anaemia, iron deficiency and parasite measures (prevalence rates, worm and egg counts) were extracted if they were available in the study. Studies that reported only parasite measures were excluded from the review.

Abstracted data includes:

Laboratory markers:
- Infection prevalence rates
- Worm counts
- Egg counts
- Iron status including haemoglobin, serum ferritin, erythrocyte protoporphyrin
- Vitamin A status

Anthropometric/nutrition measures:
- Weight
- Height
- Body mass index
- Arm circumference
- Skin fold measures

Activity levels:

Cognition/learning measures:
- Any test of cognition in children
- School absenteeism

Objective 2
Trials that reported on community-based chemotherapeutic programmes were included if they reported parasite measures, other laboratory markers or clinical measures of nutritional status as listed above.

SEARCH STRATEGY FOR IDENTIFICATION OF STUDIES
The trials register of the Cochrane Infectious Diseases Group (CIDG) was searched for relevant trials. The topic terms used were Ancylostoma duodenale/Necator americanus, Ascaris lumbricoides, Enterobius vermicularis, Trichinella spiralis, Trichuris trichiura, hookworm, roundworm, pinworm, trichinosis and whipworm. Full details of the CIDG methods and the journals searched are published in The Cochrane Library in the section on “Collaborative Review Groups”.

A second search strategy is being developed to cross check the first and will identify relevant work from nutrition-based studies.

The reviewers searched The Cochrane Controlled Trials Register, published on the Cochrane Library (Issue 2, 1997). This is a compilation of over 130,000 published trials identified by handsearching within The Cochrane Collaboration. Full details of the sources and methods used are published in The Cochrane Library.

MEDLINE was also searched (1966-present). The topic search terms were used in combination with the Cochrane highly sensitive search strategy for identifying trials. This strategy is outlined in The Cochrane Handbook, Appendix 5, Section 5.

Organisations and individuals working in the field will be contacted. A panel of individuals supporting this review and the external referees have checked the completeness of the search strategy and the efforts made to identify unpublished, ongoing and planned trials.

The reviewers will also draw on existing reviews of the topic and check the citations of all the trials identified by the above methods.

### METHODS OF THE REVIEW

All identified trials are being entered in a trial register. The inclusion criteria are being independently applied to all trials by two reviewers. If disagreement occurs the review editor will be consulted and a consensus reached.

#### Quality assessment of included trials

The methodological quality of each trial is being independently assessed by two reviewers using the guidelines of the Cochrane Infectious Diseases Group. Trials will be classified according to allocation of concealment, generation of allocation sequence and inclusion of all randomised participants.

Data will be abstracted independently by two reviewers on to previously designed and tested data abstraction tables. Data will be double-checked and discrepancies settled through discussion.

#### Data analysis

For each outcome specified, a pooled estimate of treatment effect across the studies will be calculated (odds ratio for dichotomous outcomes, weighted mean difference for continuous outcomes). A chi-square test for homogeneity will be applied and if significant, possible causes of heterogeneity will be investigated.

Percentage reduction in egg counts and mean values of skewed data will be used with care, and a statistician (member of the review panel) will work with the reviewers at all stages of the review.

### POTENTIAL CONFLICT OF INTEREST

None

### ACKNOWLEDGEMENTS

The authors wish to thank the members of the panel advising them during the progress of this review. They include:

- Dr. Marco Albonico
- Dr. Lorenzo Savioli
- Dr. Paula Williamson

This review is being conducted as part of the Effective Health Care in Developing Countries Project supported by the Department for International Development (UK). However, the DFID can take no responsibility for the data presented or the views expressed.

### SOURCES OF SUPPORT

**Internal sources of support**

- Liverpool School of Tropical Medicine, UK

**External sources of support**

- Department for International Development, UK
- European Commission (Directorate General XII), Belgium
Routine intermittent anthelminth therapy in disadvantaged populations

<table>
<thead>
<tr>
<th>Title</th>
<th>Routine intermittent anthelminth therapy in disadvantaged populations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Author(s)</td>
<td>Dickson R, Awasthi S, Demmellweek C</td>
</tr>
<tr>
<td>Contribution of author(s)</td>
<td></td>
</tr>
<tr>
<td>Issue protocol first published</td>
<td>Not provided</td>
</tr>
<tr>
<td>Issue review first published</td>
<td>Not provided</td>
</tr>
<tr>
<td>Date of last substantive update</td>
<td>22-08-1997</td>
</tr>
<tr>
<td>Date of last minor update</td>
<td>Not provided</td>
</tr>
<tr>
<td>Date edited</td>
<td>29-08-1997</td>
</tr>
<tr>
<td>Date next stage expected</td>
<td>30-11-1997</td>
</tr>
<tr>
<td>Date review re-formatted</td>
<td>Not provided</td>
</tr>
<tr>
<td>Date new studies sought but none found</td>
<td>Not provided</td>
</tr>
<tr>
<td>Date new studies found but not yet included/excluded</td>
<td>Not provided</td>
</tr>
<tr>
<td>Date new studies found and included/excluded</td>
<td>Not provided</td>
</tr>
<tr>
<td>Date reviewers' conclusions section amended</td>
<td>Not provided</td>
</tr>
<tr>
<td>Date comment/criticism added</td>
<td>Not provided</td>
</tr>
<tr>
<td>Date response to comment/criticisms added</td>
<td>Not provided</td>
</tr>
</tbody>
</table>

What's new

Contact address
Mrs Rumona C Dickson
Lecturer
International Health Division
Liverpool School of Tropical Medicine
Pembroke Place
Liverpool
L3 5QA
Merseyside
UK
Phone: +44 151 708 9393 ext: 2193
Fax: +44 151 707 1702
Email: r.dickson@liv.ac.uk

REFERENCES

Anderson 1991

Bundy 1990

Cort 1922

Evans 1995

Greenberg 1981
Routine intermittent anthelminth therapy in disadvantaged populations


Guyatt 1993

Jamison 1993

Lai 1995

Nokes 1992

Stephenson 1987

Stephenson 1993

WHO 1990
WHO. Informal consultation on intestinal helminth infections. WHO/CDS/IPI/90.

WHO 1996

Warren 1984
Warren K, Mahmoud A. Tropical and geographical medicine.

Warren 1993

World Bank 1993

Yokogawa 1985